Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Macular Edema Clinical Trials

A listing of Macular Edema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (109) clinical trials

The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema

Ocular perfusion pressure (ocular perfusion pressure - OPP), considered the driving force of ocular blood flow. Perfusion pressure is defined as the difference between the artery and vein blood pressure. Because ocular venous pressure is the same or slightly higher than the IOP (intra ocular pressure - IOP), it is ...

Phase N/A

Diabetic Retinopathy Assessed by Ultra-wide

Diabetic retinopathy imaged by ultra wide field angiography (200): the California (Optos, Scotland) allows ultrawide field pictures of 200 of the retina. This new imaging allows seeing beyond what was seen by the classic 7 ETDRS fields angiography: In pivotal studies assessing the effect of antiVEGFs on diabetic retinopathy (DR) ...

Phase N/A

Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab

Patints with diabetic macular edema (DME) will be treated with intravitreal ranibizumab injections and the effect of optimal control of internal factors (eg. glycemia, blood presure etc) on final functional (best corrected visual acuity-CBVA) and morphological (central retinal thickness-CRT) will be investigated. Patients will be randomized into two groups: Group ...

Phase

Effect of Aflibercept (Eylea ) in the Management of Bevacizumab (Avastin ) Resistant Diabetic Macular Edema

In this study patients recruitment, clinical care and follow-up will be conducted by: Dr Flavio Rezende: Principal-Investigator and Dr Radwan Ajlan: Co-Investigator. Purpose: To evaluate the visual acuity outcomes and macular changes at 6 and 12 months of intravitreal aflibercept (2.0 mg) in eyes with persistent center involved diabetic macular ...

Phase

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Efficacy of aflibercept for diabetic macular edema was demonstrated in the phase III, VIVID and VISTA studies. In these studies, aflibercept was injected using the fixed dosing regimen that an intravitreal injection was performed 5 times every 4 weeks and then every 8 weeks. Although the efficacy was comparable to ...

Phase

Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser

Diabetic macular edema (DME) is one of the major causes of visual decline among diabetic patients. Early Treatment of Diabetic Retinopathy Study has established focal/grid macular laser as the standard of treatment for clinically significant macular edema. More recently, intravitreal injections of anti-VEGF agents, either as monotherapy or in combination ...

Phase

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Lucentis injections are the current standard of care for diabetic macular edema. The only deviation from the standard of care in the current protocol is an aqueous tap before the first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.

Phase

International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients

The purpose of this research is to evaluate the effectiveness of vitrectomy for the treatment of diabetic macular edema. Diabetes is known to cause retinal blood vessels to leak, leading to swelling of the central retina (macula), and decreased vision. Removing the vitreous gel with vitrectomy surgery is known to ...

Phase N/A

Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema

Diabetic macular edema (DME) is the leading cause of blindness among people of working age. Treatment of DME included blood pressure and glycemic control, grid laser, intravitreal injection of steroids (acetonide of triamcinolone, dexamethasone implant, fluocinolone implant) or anti-Vascular endothelial growth factor (VEGF) therapy (Bevacizumab, Ranibizumab, Aflibercept) (2015). The advent ...

Phase N/A

Endpoint Management Software for Photothermal Stimulation of Macular Diseases

Sub-visible, non-damaging photothermal stimulation (532nm) exposures of 100 ms in duration resulted in enhanced expression of heat shock proteins in the retina. To test clinical efficacy of sub-visible retinal therapy using ms-range exposures of visible lasers one needs first to establish proper titration methods necessary to assure on one hand ...

Phase